Skip to content
ppharmaranks
Menu

EVEROLIMUS vs GLEEVEC

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 7, 2026·How we rate

Possible drug interaction. EVEROLIMUS and GLEEVEC are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Rating

72/100
70/100

Pharmacy pays

~$219.28 /30
~$25.80 /30

Type

RX
RX

Active ingredient

EVEROLIMUS
IMATINIB MESYLATE

Dosage forms

Tablet
Tablet

Drug class

Kinase Inhibitor
Kinase Inhibitor

Boxed warning

Half-life

about 30 hours (mean terminal elimination half-life)
—

Treats

—
Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

Which is better-rated, Everolimus or Gleevec?

By our independent rating, Everolimus scores higher — 3.6 vs 3.5 out of 5 for Gleevec. Ratings are based on FDA regulatory (recall-safety) data.

Which is cheaper, Everolimus or Gleevec?

Gleevec costs pharmacies less to acquire — about $25.80 vs $219.28 for a 30-count supply, per the CMS NADAC survey. That gap is in the pharmacy's cost of goods, not necessarily in what you pay: your price is set afterwards by your insurer and the pharmacy.

What is the difference between Everolimus and Gleevec?

Everolimus contains Everolimus, while Gleevec contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.